Skip to main content
AB

AKITA, by Finnadvance

The startup operates a biomimetic drug discovery platform that recreates micro-physiological conditions to enhance drug research efficiency. By providing reliable evaluations of drug efficacy and toxicology, the platform enables researchers to develop new therapies more cost-effectively, ultimately improving patient health outcomes.

Helsinki, FinlandFounded 201991K+ followers
Updated 3 months ago

Funding

$2.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

Funding rounds are not available yet.

Founders

Product

Features

  • The startup operates a biomimetic drug discovery platform that recreates micro-physiological conditions to enhance drug research efficiency. By providing reliable evaluations of drug efficacy and toxicology, the platform enables researchers to develop new therapies more cost-effectively, ultimately improving patient health outcomes.
This profile is AI-generated and may contain inaccuracies.